{"id":"https://openalex.org/W4401036743","doi":"https://doi.org/10.1111/bcp.16188","title":"Model\u2010based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer","display_name":"Model\u2010based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer","publication_year":2024,"publication_date":"2024-07-25","ids":{"openalex":"https://openalex.org/W4401036743","doi":"https://doi.org/10.1111/bcp.16188","pmid":"https://pubmed.ncbi.nlm.nih.gov/39054780"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.16188","doi":"https://doi.org/10.1111/bcp.16188","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcp.16188","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100777848","display_name":"Yue Zhao","orcid":"https://orcid.org/0000-0002-0814-0134","observed_orcids":["https://orcid.org/0000-0002-0814-0134"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yue Zhao","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":"https://orcid.org/0000-0002-0814-0134","affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113307302","display_name":"Akihide Tsujimoto","orcid":"https://orcid.org/0000-0002-1539-6306","observed_orcids":["https://orcid.org/0000-0002-1539-6306"]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akihide Tsujimoto","raw_affiliation_strings":["Bristol-Myers Squibb K.K., Shinjuku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb K.K., Shinjuku, Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Takafumi Ide","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Takafumi Ide","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101989330","display_name":"Jenny Zhang","orcid":"https://orcid.org/0000-0003-0853-9978","observed_orcids":["https://orcid.org/0000-0003-0853-9978"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenny Zhang","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yan Feng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Feng","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101483574","display_name":"Ling Gao","orcid":"https://orcid.org/0000-0003-1886-3931","observed_orcids":["https://orcid.org/0000-0003-1886-3931"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ling Gao","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011152885","display_name":"Akintunde Bello","orcid":"https://orcid.org/0009-0007-5186-3577","observed_orcids":["https://orcid.org/0009-0007-5186-3577"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Akintunde Bello","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103164539","display_name":"Amit Roy","orcid":"https://orcid.org/0000-0003-2140-1455","observed_orcids":["https://orcid.org/0000-0003-2140-1455"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit Roy","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, United States","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5100777848"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":4550,"currency":"USD","value_usd":4550},"apc_paid":null,"fwci":0.5105,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.66153872,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"90","issue":"11","first_page":"2920","last_page":"2930"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9678000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9678000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.012600000016391277,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0052999998442828655,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/esophageal-cancer","display_name":"esophageal cancer","score":0.9100000262260437},{"id":"https://openalex.org/keywords/gastroesophageal-junction-cancer","display_name":"gastroesophageal junction cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/adjuvant-immunotherapy","display_name":"adjuvant immunotherapy","score":0.9639999866485596},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.8920000195503235},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.859000027179718},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7870000004768372},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.8479999899864197},{"id":"https://openalex.org/keywords/dosing-regimen-optimization","display_name":"dosing regimen optimization","score":0.8270000219345093},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.7710000276565552},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6899999976158142}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8360637426376343},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8265724182128906},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.7580903768539429},{"id":"https://openalex.org/C2909600360","wikidata":"https://www.wikidata.org/wiki/Q1029907","display_name":"Gastroesophageal Junction","level":4,"score":0.6928104162216187},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6418446898460388},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5817579627037048},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5466218590736389},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.500490665435791},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.49288058280944824},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4901517331600189},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3800918161869049},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34297996759414673},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.15282973647117615},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.10803091526031494},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004938","descriptor_name":"Esophageal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004938","descriptor_name":"Esophageal Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D004938","descriptor_name":"Esophageal Neoplasms","qualifier_ui":"Q000601","qualifier_name":"surgery","is_major_topic":true},{"descriptor_ui":"D004943","descriptor_name":"Esophagogastric Junction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013274","descriptor_name":"Stomach Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D013274","descriptor_name":"Stomach Neoplasms","qualifier_ui":"Q000601","qualifier_name":"surgery","is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/bcp.16188","doi":"https://doi.org/10.1111/bcp.16188","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcp.16188","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:39054780","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39054780","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332611","display_name":"Bristol-Myers Squibb Canada","ror":"https://ror.org/01r00g076"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1975154824","https://openalex.org/W2057499380","https://openalex.org/W2102381872","https://openalex.org/W2160834915","https://openalex.org/W2565164803","https://openalex.org/W2567068937","https://openalex.org/W2587297698","https://openalex.org/W2803354665","https://openalex.org/W2912537198","https://openalex.org/W2946271224","https://openalex.org/W2987002164","https://openalex.org/W2999177201","https://openalex.org/W3011867057","https://openalex.org/W3148827278","https://openalex.org/W3158319387","https://openalex.org/W4323050139"],"related_works":["https://openalex.org/W2914696624","https://openalex.org/W2999177201","https://openalex.org/W4407678373","https://openalex.org/W3125359479","https://openalex.org/W2754947201","https://openalex.org/W2984796633","https://openalex.org/W4382799116","https://openalex.org/W2945778047","https://openalex.org/W4290975543","https://openalex.org/W4416143200"],"abstract_inverted_index":{"AIMS:":[0],"Nivolumab":[1,129],"is":[2],"approved":[3],"as":[4,38],"adjuvant":[5,39,256],"treatment":[6,40],"in":[7,41,253],"subjects":[8,42,69],"with":[9,43,136,249,255],"resected":[10,44],"oesophageal":[11],"or":[12,204],"gastroesophageal":[13],"junction":[14],"cancer":[15],"(EC/GEJC)":[16],"based":[17],"on":[18],"results":[19],"from":[20,67,70,85,88],"the":[21,101,146,155,176,181,195,231,237,242],"pivotal":[22],"CheckMate":[23,89],"577":[24],"trial.":[25],"We":[26],"present":[27],"a":[28,47,226],"model-based":[29],"clinical":[30,65,73],"pharmacology":[31],"profiling":[32],"and":[33,95,106,112,139,157,167,188,240],"benefit-risk":[34],"assessment":[35],"of":[36,117,141,160,186,198,233,244],"nivolumab":[37,61,104,161],"EC/GEJC":[45],"supporting":[46],"less":[48,250],"frequent":[49,251],"dosing":[50,247,252],"regimen.":[51,183],"METHODS:":[52],"Population":[53],"pharmacokinetic":[54],"(popPK)":[55],"analysis":[56],"was":[57,131],"conducted":[58],"to":[59,114,133,219],"characterize":[60],"pharmacokinetics":[62],"(PK)":[63],"using":[64],"data":[66,84],"1493":[68],"seven":[71],"monotherapy":[72],"studies":[74],"across":[75],"multiple":[76],"solid":[77],"tumours.":[78],"The":[79,223],"exposure-response":[80],"(E-R)":[81],"analyses":[82,224],"included":[83],"756":[86],"patients":[87,254],"577.":[90],"E-R":[91,173,228],"relationships":[92,174],"for":[93,110,126,165,210],"efficacy":[94],"safety":[96],"were":[97,163,192],"characterized":[98],"by":[99,180,214,236],"evaluating":[100],"relationship":[102,229],"between":[103,194],"exposure":[105,130,162,177],"disease-free":[107],"survival":[108],"(DFS)":[109],"efficacy;":[111],"time":[113],"first":[115],"occurrence":[116],"Grade":[118],"\u22652":[119],"immune-mediated":[120],"adverse":[121],"events":[122],"(Gr2":[123],"+":[124,143,169,190],"IMAEs)":[125],"safety.":[127],"RESULTS:":[128],"found":[132],"be":[134],"associated":[135],"both":[137],"DFS":[138,166,187],"risk":[140],"Gr2":[142,168,189],"IMAEs.":[144],"However,":[145],"hazard":[147],"ratios":[148],"(HRs)":[149],"(95%":[150],"confidence":[151],"interval":[152],"[CI])":[153],"at":[154],"5th":[156],"95th":[158],"percentiles":[159],"similar":[164,193],"IMAEs,":[170],"indicating":[171],"flat":[172,227],"within":[175],"range":[178,232],"produced":[179,235],"studied":[182,238],"Model-predicted":[184],"probability":[185],"IMAEs":[191],"two":[196],"regimens":[197],"240":[199],"mg":[200,206,216],"every":[201,207],"2":[202],"weeks":[203,209,212],"480":[205,215],"4":[208],"16":[211],"followed":[213],"Q4W":[217],"up":[218],"1":[220],"year.":[221],"CONCLUSIONS:":[222],"demonstrated":[225],"over":[230],"exposures":[234],"regimen":[239,248],"supported":[241],"approval":[243],"an":[245],"alternative":[246],"EC/GEJC.":[257]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-07-27T00:00:00"}